Federal Grant

Federal Grant funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.

RFA-DA-26-055: Accelerating the Pace of Substance Use Research Using Existing Data (R01)

NIH’s NIDA RFA-DA-26-055 supports R01 projects that use existing social, behavioral, administrative, and neuroimaging datasets to advance prevention, treatment, and service-delivery research on substance use, HIV, and related outcomes, without collecting primary data.

Status: Open Type: Grant Amount: NIDA intends to commit $2 million in FY2026 for 2-4 applications, plus an additional $2 million … Deadline: Dec 3, 2026 Location: United States and Global

RFA-DA-26-056: Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)

NIDA's RFA-DA-26-056 funds R21 projects that use existing social, behavioral, administrative, and neuroimaging data to study substance use, related disorders, prevention, HIV, and service use without new data collection.

Status: Open Type: Grant Amount: $275,000 maximum in direct costs over two years; no more than $200,000 in any single year Deadline: Dec 3, 2026 Location: United States and International

RFA-DK-26-315: Advancing Research on Digital Health Technology for Type 2 Diabetes (R01)

NIH RFA-DK-26-315 is a clinical-trial R01 opportunity for U.S. institutions to test digital health approaches to improve type 2 diabetes management, with submission cycles in 2026 and 2027 and a strict non-responsiveness rule against tool-building and T1D-only projects.

Status: Open Type: Grant Amount: Funds available: $1.5M in FY2026 and $3.0M in FY2027-2030 Deadline: Oct 6, 2026 Location: United States

RFA-DK-27-126: Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning communitY - Coordinating Center (KUH-FAMILY) (U24 - Clinical Trials Not Allowed)

A completed NIH/NIDDK cooperative-agreement opportunity for one coordinating center to unite KUH training programs, support career development, and administer a national peer-to-peer research community.

Status: Historical Type: Grant Amount: Approximately $800,000 in direct costs per year excluding the Opportunity Pool, plus $200,000 or … Deadline: Historical reference Location: United States

RFA-ES-25-002: Environmental Health Sciences Core Centers Program (P30 Clinical Trials Optional)

The National Institute of Environmental Health Sciences invites U.S. applicants to propose Environmental Health Sciences Core Centers through the P30 mechanism. The next listed application due date is April 20, 2027.

Status: Open Type: Grant Amount: NIEHS intends to commit $6.0M in FY 2026 for up to 4 awards Deadline: Apr 20, 2027 Location: United States

RFA-HD-27-007: Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research

This NIH RFA requests grant applications that use existing HIV/AIDS archives and biospecimen repositories to generate high-impact research on maternal and pediatric HIV outcomes.

Status: Open Type: Grant Amount: $1,000,000 expected FY2027 set-aside Deadline: Oct 21, 2026 Location: United States

RFA-HL-26-003: NHLBI Emerging Investigator Award (EIA) (R35, Clinical Trial Optional)

NIH’s NHLBI Emerging Investigator Award (R35, clinical trial optional) supports established HLBS investigators with at least two NHLBI R01-equivalent grants for up to seven years of flexible, program-level funding, with the next listed due date on 19 February 2027.

Status: Open Type: Grant Amount: Funding level determined by NHLBI based on peer review and program factors Deadline: Feb 19, 2027 Location: United States

RFA-HL-26-017: NIH Catalyze Product Definition for Small Molecules and Biologics (R61/R33)

NIH's RFA-HL-26-017 supports early-stage translational projects that generate and validate therapeutic candidates for HLBS diseases through a phased R61/R33 development pathway.

Status: Rolling Type: Grant Amount: Up to $400,000 direct costs per year in the R61 phase and up to $400,000 direct costs per year … Deadline: Rolling or ongoing Location: United States

RFA-HL-26-019: Catalyze Product Definition - Medical Device Prototype Design/Testing and Disease Target Identification and Assay Development (R61/R33; Clinical Trial Not Allowed)

NIH NHLBI Catalyze Product Definition NOFO for early-stage device, diagnostic, and research-tool development in heart, lung, blood, and sleep diseases. The next new-application due date is October 21, 2026.

Status: Open Type: Grant Amount: Up to $300,000 in NIH direct costs per year during R61 and up to $300,000 per year during R33 Deadline: Oct 21, 2026 Location: United States, U.S. territories and Foreign components of eligible U.S. organizations

RFA-HL-27-004: Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)

NIH’s NHLBI RFA-HL-27-004 is a limited-competition R03 small grant opportunity to help current and recently completed NHLBI K01/K08/K23/K25 awardees advance toward independent funding through a short, NIH-funded pilot- to proof-of-concept scale project.

Status: Open Type: Grant Amount: Direct costs up to $85,000 per year; maximum 2-year project period Deadline: Oct 6, 2026 Location: United States